Company Overview
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Why Investors Should Care
Revenue has grown at a 29.6% CAGR over the past five years.
Operating margin of 53.4% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $234.60M (+157.0% YoY); net profit $-13.23M.
- Trailing 12 Months Year-on-year growth — revenue +23.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 29.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 29.58% |
| 1 Year: | 23.50% |
Stock Price Performance
| 1 Year: | +252.78% |
| 6 Months: | -17.24% |
| 3 Months: | -9.10% |
| 1 Month: | -5.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 29.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANAB AnaptysBio, Inc. R2KR3KPHARMA | 48.73 | -50.76 | $1.46B | 0.00% | 14.70% | -114.55% | 29.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 5.00M | - | 0 | 5.00M | 0 | - | 15.00M | 0 | 0 | 11.25M | 30.03M | 20.89M | 970.00K | 1.22M | 1.29M | 1.37M | 3.46M | 3.32M | 7.18M | 10.97M | 30.02M | - | 27.77M | 22.26M | 76.32M | 108.25M | 25.56M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.31M | 48.43M | 41.62M | 41.35M | 60.19M |
| Operating Income | -1.14M | 2.36M | -1.07M | -3.17M | -9.99M | -2.56M | -9.09M | -7.15M | -15.76M | -14.41M | -16.89M | -19.66M | -24.77M | -26.66M | -33.74M | -22.26M | -10.25M | -22.64M | -24.34M | -18.36M | -533.00K | -6.76M | -31.75M | -27.80M | -29.63M | -44.40M | -40.14M | -37.73M | -42.20M | -40.32M | -22.76M | - | -27.54M | -26.17M | 34.70M | 66.90M | -34.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.62M | -18.38M | 38.24M | 70.01M | -31.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.06M | 19.61M | 22.52M | 19.71M | 20.86M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.28M | -38.59M | 15.11M | 49.70M | -52.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.00K | 39.00K | 0 | 81.00K | 40.00K |
| Net Income | -888.00K | 2.32M | -1.11M | - | -11.44M | -2.68M | -9.09M | - | -15.09M | -13.62M | -15.96M | - | -22.08M | -23.96M | -31.03M | - | -8.26M | -21.55M | -23.77M | -18.16M | -429.00K | -6.67M | -36.26M | -32.55M | -33.50M | -44.26M | -39.84M | -37.31M | -43.94M | -46.66M | -32.85M | - | -39.33M | -38.63M | 15.11M | 49.61M | -52.88M |
| Diluted EPS | -0.34 | 0.05 | -0.42 | -1.73 | -0.75 | -0.13 | -0.45 | -0.30 | -0.63 | -0.57 | -0.66 | -0.64 | -0.82 | -0.89 | -1.15 | -0.75 | - | -0.79 | -0.87 | -0.66 | -0.02 | -0.24 | -1.31 | -1.15 | -1.18 | -1.58 | -1.50 | -1.41 | -1.64 | -1.71 | -1.14 | - | -1.28 | -1.34 | 0.52 | 1.58 | -1.84 |
| R&D Expense | 4.79M | 2.33M | 3.28M | - | 7.93M | 7.21M | 6.70M | - | 11.81M | 10.58M | 17.88M | - | 20.63M | 27.35M | 29.93M | - | 20.97M | 17.95M | 19.54M | 24.18M | 25.31M | 22.22M | 22.52M | 20.84M | 22.06M | 34.96M | 32.92M | 30.88M | 37.04M | 42.00M | 42.21M | - | 41.18M | 37.82M | 31.41M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.57M | 16.68M | 10.00M | 5.00M | 8.00M | 75.00M | 63.17M | 10.29M | 17.16M | 91.28M | 234.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 125.44M | 174.23M | 206.23M | 186.71M |
| Operating Income | -3.32M | -3.02M | -28.78M | -66.72M | -107.43M | -23.88M | -56.81M | -115.15M | -157.07M | -114.95M | 47.90M |
| EBITDA | - | - | - | - | - | - | - | -105.26M | -143.16M | -92.74M | 69.25M |
| Interest Expense | - | - | - | - | - | - | - | 21.11M | 18.08M | 50.09M | 79.89M |
| Pretax Income | - | - | - | - | - | - | - | -128.70M | -163.62M | -145.23M | -13.07M |
| Tax Provision | - | - | - | - | - | - | - | 24.00K | -4.00K | 3.00K | 164.00K |
| Net Income | -5.41M | -4.26M | -30.07M | -61.66M | -97.34M | -19.93M | -57.80M | -128.72M | -163.62M | -145.23M | -13.23M |
| Diluted EPS | - | -1.62 | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.46 |
| R&D Expense | 17.30M | 15.42M | 29.44M | 56.20M | 99.34M | 80.03M | 98.50M | 88.80M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.18M | 329.36M | 509.00M | 435.20M | 416.55M | - | 610.38M | 452.39M | 483.83M | 364.39M |
| Current Assets | - | - | - | - | - | - | - | - | 447.20M | 406.83M | 431.88M | 350.25M |
| Cash & Equivalents | - | - | 51.23M | 81.19M | 113.60M | 171.02M | 250.46M | - | 71.31M | 35.97M | 123.08M | 238.20M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 1.42M | 6.85M | 40.77M | 33.85M |
| Total Liabilities | - | - | - | - | - | - | - | - | 348.28M | 364.29M | 412.97M | 327.19M |
| Current Liabilities | - | - | 5.71M | 14.09M | 21.84M | 29.54M | 19.82M | - | 26.05M | 37.44M | 45.43M | 38.62M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 19.45M | 17.81M | 16.04M | 14.11M |
| Total Equity | -30.84M | -35.18M | -38.25M | 307.58M | 486.37M | 405.01M | 396.73M | - | 262.10M | 88.10M | 70.87M | 37.21M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 28.51M | 26.60M | 30.47M | 28.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.69M | -9.03M | -19.44M | -48.51M | -69.52M | -14.16M | - | -73.59M | -120.80M | -135.34M | 19.70M |
| Investing Cash Flow | -238.00K | -50.00K | -243.06M | -142.45M | 131.43M | 94.47M | - | -394.85M | 144.75M | 95.40M | 228.03M |
| Financing Cash Flow | 39.40M | 8.63M | 292.45M | 223.36M | -4.49M | -879.00K | - | 44.02M | -59.30M | 127.05M | -132.61M |
| Capital Expenditure | -238.00K | -50.00K | -290.00K | -1.06M | -805.00K | -569.00K | - | -358.00K | -807.00K | -358.00K | -87.00K |
| Free Cash Flow | -9.93M | -9.08M | -19.73M | -49.57M | -70.32M | -14.73M | - | -73.95M | -121.61M | -135.69M | 19.61M |
| Net Change in Cash | - | - | - | - | - | - | - | -424.42M | -35.34M | 87.11M | 115.12M |
| Share Buybacks | 0 | 1.00K | 0 | 0 | - | - | 0 | 0 | 50.00M | 456.00K | 68.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -18.9% | -18.1% | -287.8% | -1,334.4% | -1,342.9% | -31.8% | -89.9% | -1,119.4% | -915.5% | -125.9% | 20.4% |
| Net Margin % | -30.8% | -25.5% | -300.7% | -1,233.1% | -1,216.7% | -26.6% | -91.5% | -1,251.3% | -953.7% | -159.1% | -5.6% |
| ROE % | 15.4% | 11.1% | -9.8% | -12.7% | -24.0% | -5.0% | - | -49.1% | -185.7% | -204.9% | -35.6% |
| ROCE % | - | -5.4% | -9.1% | -13.7% | -26.5% | -6.0% | - | -19.7% | -37.9% | -26.2% | 14.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 26.36% | 7.88M | $362.09M |
| 2 | Blackrock Inc. | 6.17% | 1.84M | $84.73M |
| 3 | Tang Capital Management, LLC | 4.45% | 1.33M | $61.15M |
| 4 | State Street Corporation | 4.30% | 1.29M | $59.10M |
| 5 | Vanguard Capital Management LLC | 3.03% | 906.23K | $41.64M |
| 6 | Affinity Asset Advisors, Llc | 2.76% | 826.11K | $37.96M |
| 7 | Sanofi | 2.75% | 821.92K | $37.77M |
| 8 | Millennium Management Llc | 2.70% | 807.32K | $37.10M |
| 9 | Woodline Partners LP | 2.40% | 717.01K | $32.95M |
| 10 | 683 Capital Management LLC | 2.21% | 660.00K | $30.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANAB
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after median follow up of more than 2 yearsJem…
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
AnaptysBio (ANAB) has drawn fresh attention after recent trading left the stock down about 18% over the past month and roughly 30% over the past 3 months. That slump now frames how investors assess its royalty driven biotech model. Short te…
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
AnaptysBio has delivered very strong gains over the past few years, which puts a spotlight on whether the current share price is properly supported by its earnings profile. After such a run, the key issue for you is whether the recent marke…
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valu…
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ANAB — Frequently Asked Questions
What is the current share price of AnaptysBio, Inc. (ANAB)?
As of 2026-10-23 16:27 PDT, AnaptysBio, Inc. (ANAB) trades at $48.73 on NasdaqGS. Its 52-week range is $12.93 to $69.81.
What is the market capitalisation of ANAB?
AnaptysBio, Inc. (ANAB) has a market capitalisation of $1.46B on NasdaqGS.
What is the P/E ratio of ANAB?
ANAB trades at a trailing price-to-earnings (P/E) ratio of -50.76. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 129.07.
What is the return on equity (ROE) of ANAB?
ANAB has a return on equity (ROE) of -114.55%. Its return on capital employed (ROCE) is 14.70%.
Is ANAB a good stock to buy?
This page provides a data-driven analysis of AnaptysBio, Inc. (ANAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.